AlphAIalphai — Financial news for AI agents
investing.comAUG 123 min read$HBIO

Benchmark raises Harvard Bioscience stock price target on revenue beat

Benchmark raised its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00 and kept a Speculative Buy rating after Q2 results. Q2 revenue was $22.7M, above guidance and consensus. Full-year 2026 revenue growth guidance was lifted to 3% to 5%. Adjusted gross margin target was lowered to 57% to 59%.

Original reporting
investing.com
Published Aug 12, 2026, 2:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMarket movers
Primary signal
$HBIO
Bullish
medium confidence
Mentioned
$HBIO
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$HBIOBullishMed
01

Why it matters

The key tradable inputs are the raised full-year revenue growth range, the updated margin and EBITDA targets, and the analyst’s new $7.50 price target based on a 0.6x NTM revenue multiple.

02

Market read

Traders may reassess HBIO’s valuation and near-term expectations given the revenue beat, raised growth guidance, and a fresh analyst target update.

03

What to watch

The gross margin target was lowered (57% to 59% vs prior 58% to 60%), so the valuation rerating may be sensitive to execution on cost discipline and Project Viking savings by 2027.

Relevance 7/10Novelty 6/10Timing: today, post Q2 results with same-day analyst price-target raise

Background

Benchmark maintained a Speculative Buy rating and updated its valuation after Harvard Bioscience reported Q2 results and issued updated 2026 guidance.

Company-level read

Ticker impact

$HBIOBullishMedium confidence
Context

Benchmark raised HBIO’s price target to $7.50 after Q2 revenue beat guidance and the company lifted 2026 revenue growth guidance to 3% to 5%.

Expected impact

Likely modest positive bias for HBIO as traders price in the raised revenue growth range and margin/EBITDA targets.

Evidence & confidence

The article provides concrete Q2 results, raised full-year revenue guidance, and a new analyst price target, but it is still an analyst action rather than a new company filing or contract award.

Market effects

Sector

Supports sentiment for small-cap life-science tools/biotech instrumentation names tied to cellular and molecular workflows.

Regional

No direct regional contagion beyond mention of Americas and Asia-Pacific growth rates.

Global

Limited global read-through; mostly company-specific guidance and analyst valuation update.

Counterpoint

What could challenge this read

Despite the revenue beat and higher guidance, the company is still forecast to be unprofitable in fiscal 2026, which can cap upside if margins or EBITDA conversion disappoint.

Key entities

  • company
    Harvard Bioscience Inc.

    NASDAQ-listed life-science tools company reporting Q2 results and updated 2026 guidance; subject of the analyst price-target change.

  • analyst_firm
    Benchmark

    Raised HBIO’s price target to $7.50 from $6.00 while keeping a Speculative Buy rating.

Read at source← All news

Related articles

AUG 18
$HBIOMedAI 8/10

Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience (HBIO) reported Q2 2026 revenue of $22.7M, up 11%, and adjusted EBITDA of $1.7M, up 11%. Full-year revenue guidance was raised to 3-5% growth, but gross margin guidance was lowered to 57-59% due to product and geographic mix shifts. The company expects $3M in cost savings from Project Viking in 2027. Americas and APAC regions showed strong growth, while Europe grew modestly. Adjusted EPS was -$0.14, and Q3 revenue guidance is $21.0M-$22.6M.

fool.com6 min
AUG 13
$HBIOMed

Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary

Harvard Bioscience (HBIO) reported Q2 2026 revenue up 11%, driven by CRO demand and double-digit growth in telemetry and CMT portfolios. China sales rose on its “Made in China” BTX line. Recurring revenue reached 55%. Full-year guidance raised to 3% to 5% growth, but adjusted gross margin cut 100 bps to 57% to 59%, with Project Viking cost savings.

yahoo.com6 min
AUG 11
$HBIOMed

HARVARD BIOSCIENCE INC (HBIO): Results of Operations and Financial Condition

HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2026 Financial Results · Second Quarter 2026 Revenue Growth of 11% Year Over Year to $22.7 Million · Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth HOLLISTON, Mass.,

SEC EDGAR 8-K6 min
AUG 23
$NVDAMed

Nvidia says it’s raising some prices more than 15%

Nvidia plans to raise prices for AI chip servers by over 15% due to rising memory costs, according to Bloomberg. The company is also investing $6 billion to license AI technology from startup Poolside, competing with firms like OpenAI and Anthropic. Anthropic faces pressure as customers opt for cheaper AI models ahead of its potential IPO.

yahoo.com2 min
AUG 23
$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

genengnews.com3 min